Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $17.43, but opened at $16.70. Daiichi Sankyo shares last traded at $17.2450, with a volume of 13,443 shares.
Analyst Upgrades and Downgrades
DSNKY has been the subject of a number of recent analyst reports. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research downgraded Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce”.
Check Out Our Latest Analysis on DSNKY
Daiichi Sankyo Price Performance
The stock’s fifty day moving average price is $17.76 and its 200-day moving average price is $17.52. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The firm has a market cap of $31.98 billion, a PE ratio of 17.52, a P/E/G ratio of 1.78 and a beta of -0.10.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.08. Daiichi Sankyo had a net margin of 12.13% and a return on equity of 16.31%. The firm had revenue of $3.77 billion for the quarter, compared to the consensus estimate of $3.58 billion. As a group, equities analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current fiscal year.
About Daiichi Sankyo
Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
